Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Thyas Obtains Exclusive Rights to Manufacture Induced Pluripotent Stem Cells-Derived Killer T Cells for Autologous Immunotherapy

pharmafocusasiaJanuary 21, 2019

Tag: Thyas , Autologous Immunotherapy , T cells , IPS

PharmaSources Customer Service